Dr Alexander Tarr's Outputs (2)

Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants (2018)
Journal Article
Khera, T., Behrendt, P., Bankwitz, D., Brown, R. J., Todt, D., Doepke, M., Khan, A. G., Schulze, K., Law, J., Logan, M., Hockman, D., Wong, J. A. J.-X., Dold, L., Gonzalez-Motos, V., Spengler, U., Viejo-Borbolla, A., Ströh, L. J., Krey, T., Tarr, A. W., Steinmann, E., …Pietschmann, T. (2019). Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 70(4), 593-602. https://doi.org/10.1016/j.jhep.2018.11.003

© 2018 European Association for the Study of the Liver Background & Aims: Induction of cross-reactive antibodies targeting conserved epitopes of the envelope proteins E1E2 is a key requirement for an hepatitis C virus vaccine. Conserved epitopes like... Read More about Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.

Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? (2018)
Journal Article
Abo-zeid, Y., Urbanowicz, R. A., Thomson, B. J., Irving, W. L., Tarr, A. W., & Garnett, M. C. (2018). Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?. International Journal of Pharmaceutics, 547(1-2), https://doi.org/10.1016/j.ijpharm.2018.06.027

Virus infections cause diseases of different severity ranged from mild infection e.g. common cold into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections. Althou... Read More about Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?.